RT Journal Article
SR Electronic
T1 Carnosine supplementation improves glucose control in adults with pre-diabetes and type 2 diabetes: a randomised controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.18.23287432
DO 10.1101/2023.03.18.23287432
A1 Hariharan, Rohit
A1 Cameron, James
A1 Menon, Kirthi
A1 Mesinovic, Jakub
A1 Jansons, Paul
A1 Scott, David
A1 Lu, Zhong X
A1 de Courten, Maximilian
A1 Feehan, Jack
A1 de Courten, Barbora
YR 2023
UL http://medrxiv.org/content/early/2023/03/23/2023.03.18.23287432.abstract
AB Type 2 diabetes (T2DM) is a major cause of morbidity and mortality globally. Carnosine, a naturally occurring dipeptide, has anti-inflammatory, antioxidant, and anti-glycating effects, with preliminary evidence suggesting it may improve important chronic disease risk factors in adults with cardiometabolic conditions. In this randomized controlled trial, 43 adults (30%F) living with prediabetes or T2DM consumed carnosine (2 grams) or a matching placebo daily for 14 weeks to evaluate its effect on glucose metabolism assessed via 2 hr, 75g oral glucose tolerance test. Secondary outcomes included body composition analysis by dual energy x-ray absorptiometry (DEXA), calf muscle density by pQCT and anthropometry. Carnosine supplementation decreased blood glucose at 90 minutes (−1.31mmol/L; p=0.02) and 120 minutes (−1.60mmol/L, p=0.02) and total glucose area under the curve (−3.30mmol/L; p=0.04) following an oral glucose tolerance test. There were no additional changes in secondary outcomes. The carnosine group results remained significant before and after adjustment for age, sex, and change in weight (all>0.05), and in further sensitivity analyses accounting for missing data. There were no significant changes in insulin levels. Likely mechanisms may include changes to hepatic glucose output explaining the observed reduction in blood glucose without changes in insulin secretion following carnosine supplementation. This study provides preliminary support for larger trials evaluating carnosine as a potential treatment for prediabetes and the early stages of T2DM.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02917928Funding StatementCASS Australia, Flamma Group, the Royal Australasian College of PhysiciansAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Monash University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors